TrialJNCI cancer spectrum2022

Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two Placebo-Controlled, Randomized Phase 3 Studies (POLAR-A/POLAR-M).

Per Pfeiffer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.